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Abstract Cell-level kinetic models for therapeutically
relevant processes increasingly beneﬁt the early stages of
drug development. Later stages of the drug development
processes, however, rely on pharmacokinetic compartment
models while cell-level dynamics are typically neglected.
We here present a systematic approach to integrate cell-
level kinetic models and pharmacokinetic compartment
models. Incorporating target dynamics into pharmacoki-
netic models is especially useful for the development of
therapeutic antibodies because their effect and pharmaco-
kinetics are inherently interdependent. The approach is
illustrated by analysing the F(ab)-mediated inhibitory
effect of therapeutic antibodies targeting the epidermal
growth factor receptor. We build a multi-level model for
anti-EGFR antibodies by combining a systems biology
model with in vitro determined parameters and a pharma-
cokinetic model based on in vivo pharmacokinetic data.
Using this model, we investigated in silico the impact of
biochemical properties of anti-EGFR antibodies on their
F(ab)-mediated inhibitory effect. The multi-level model
suggests that the F(ab)-mediated inhibitory effect saturates
with increasing drug-receptor afﬁnity, thereby limiting
the impact of increasing antibody afﬁnity on improving the
effect. This indicates that observed differences in the
therapeutic effects of high afﬁnity antibodies in the market
and in clinical development may result mainly from Fc-
mediated indirect mechanisms such as antibody-dependent
cell cytotoxicity.
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Introduction
Biotechnologically engineered proteins such as monoclonal
antibodies (mAbs) have demonstrated their potential in
therapies for cancer and other complex diseases [1]. Due to
their ability to speciﬁcally bind targets, they allow to
modulate speciﬁc cellular targets and signaling pathways.
Various therapeutic proteins on the market use their bind-
ing speciﬁcity to inhibit cell surface receptors with critical
biologic function. At the same time, many targeted receptor
systems also constitute a degradation mechanism for such
drugs because binding leads to endocytosis and ultimately
degradation of the drug. A thorough understanding of the
complex interplay between a drug’s pharmacokinetics and
its effect is largely missing.
Empirical or semi-mechanistic compartmental models
are typically used to analyze preclinical or clinical phar-
macokinetic data of protein drugs [2–6]. In these models,
the interaction of the drug with its target is represented by
an empirical or semi-mechanistic term, accounting for the
saturable degradation capacity of the target system. Fur-
ther, models of target mediated drug disposition (TMDD)
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for drugs that bind with high afﬁnity and to a signiﬁcant
extent to a pharmacologic target such as an enzyme,
receptor, or transporter [7–9]. This is accomplished by
describing the target as an additional binding compartment.
In systems biology, detailed mechanistic models of
targets at the cell level have proven valuable for identifying
potent drug targets [10]. Such mathematical models allow
identifying and ranking potential targets in cellular net-
works for achieving speciﬁc downstream effects [11, 12].
A recent prominent example is the use of a kinetic model to
identify critical components in ErbB signaling pathways
[13] and was the basis for the development of a therapeutic
antibody that targets the ErbB3 receptor and is currently in
Phase II clinical trials [14].
Linking pharmacokinetic and systems biology model-
ling approaches allows a multi-level description of the
system as a whole. These kinds of systems pharmacology
models are therefore increasingly advocated by researchers
as well as regulators [15]. A combined model for a drugs’
pharmacokinetic and its cellular effect would be especially
valuable for therapeutic proteins where drug effect and
pharmacokinetics are inherently interdependent. As models
of both, whole-body pharmacokinetics and cellular target
dynamics, are becoming more abundant, the main bottle-
neck in developing multi-level systems pharmacology
models is in how to interface the cellular and whole body
layers levels.
The objective of this article is to develop a systematic
approach to integrate the cellular-level into compartment
models of drug pharmacokinetics. Due to their important
role in the treatment of cancer, we have developed a cell-
level pharmacokinetic/pharmacodynamic model for anti-
bodies antagonistically inhibiting the epidermal growth
factor receptor (EGFR). The binding of one of its natural
ligands to the EGFR results in the activation of signal
transduction pathways that mediate a variety of cellular
responses [16] which include cell proliferation, differenti-
ation, survival, and angiogenesis [17]. We illustrate our
approach by developing a cell-level PK/PD model for the
anti-EGFR therapeutic antibody zalutumumab in cyno-
molgus monkeys. The model integrates a compartment
model developed based on in vivo plasma data for zal-
utumumab [6], and a receptor trafﬁcking model based on in
vitro data of the EGFR [18–24].
mAbs comprise a variable target-speciﬁc F(ab) region
and aconstant Fc region [4]. The target-speciﬁc part rec-
ognizes the targeted protein, whereas the constant part is
involved in different mechanism which determine the
pharmacokinetics as well as trigger indirect therapeutic
effects such as triggering antibody-dependent cell cyto-
toxicity. Using our combined model and integrating pre-
clinical pharmacokinetic data we have investigated in silico
the impact of biochemical properties of anti-EGFR anti-
bodies on the F(ab)-mediated inhibitory effect. This new
kind of model allows to identify in silico opportunities and
limitations for the optimization of biophysical properties of
future therapeutic antibodies.
Theoretical
Compartment model of in vivo therapeutic antibody
pharmacokinetics
The pharmacokinetic part of the multi-level model will be
based on Zalutumumab (2F8), an IgG1 antibody against
EGFR that inhibits tumor growth in xenograft models and
has shown promising results in phase I/II clinical trials [25,
26]. Lammerts van Bueren et al. [6] developed a 3-com-
partment pharmacokinetic model of zalutumumab in
cynomolgus monkeys which accurately describes experi-
mental plasma data for high and low doses (Fig. 1a). In the
model, Cpla and Cint represent the concentrations of the
mAb in plasma (with volume Vpla) and the interstitial space
(with volume Vint). ARS denotes the amount of drug that is
bound to the targeted receptor. The parameters qpi and qip
denote the transfer ﬂows between the plasma and intersti-
tial compartment, kb denotes some large ’artiﬁcial’ rate
constant that ensures quasi-steady state conditions between
the unbound drug concentration in the interstitial space and
the drug bound to the receptor. The amount of drug bound
to the receptor is modeled in terms of a Michaelis Menten
term with Bmax PK denoting the maximal binding capacity
of the therapeutic protein to EGFR and KM,PK denoting the
concentration corresponding to the half-maximal binding
capacity. The rate constant of elimination of EGFR by
internalization and degradation is denoted by kel, while the
target-independent clearance such as proteolysis in the
blood [27] is denoted by CLlin. The values of the param-
eters as used by Lammerts van Bueren et al. are given in
Table 1. The rate of change of the molecular concentra-
tions and amount is given by:
1
Vpla
dCpla
dt
¼  qpiCpla þ qipCint   CLlin   Cpla ð1Þ
1 We transformed the originally published system of difference
equations [6, Supplement] into a corresponding continuous system of
ordinary differential equations. The originally published equations in
[6, Supplement] are identical to a certain discretization of the system
of ODEs (1–3). The advantage of stating the system as continuous
ODEs is that subsequently any numerical scheme can be used to solve
them, in particular high accuracy ODE solver with adaptive step size
control. See also [28].
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123Vint
dCint
dt
¼þ qpiCpla   qipCint   kb
Bmax;PK   Cint
KM;PK þ Cint
  ARS
  
ð2Þ
dARS
dt
¼ kb
Bmax;PK   Cint
KM;PK þ Cint
  ARS
  
  kelARS ð3Þ
In the above model of Lammerts van Bueren et al., the
interaction of zalutumumab with its target (represented by the
MichaelisMententerm)accountsforthenon-linearfeedbackof
the receptor system on the mAb concentration in the interstitial
space,knownasreceptormediatedendocytosis.Withregardto
drug effect, the above model does not allow us, however, to
analyze the inhibitory effect of zalutumumab on the targeted
receptors.Moreover,theMichaelisMenteninteractiontermisa
hybrid parameter in the sense that it combines drug related
properties—likebindinganddissociationrateconstantsaswell
as internalisation rate constants—with receptor system param-
eters—like receptor synthesis, degradation and internalization
[28]. As a consequence, the parameters Bmax PK and KM,PK are
speciﬁc tozalutumuab.An analysis of the impactofchanges in
thedrug-receptorinteractionisnotfeasiblewiththismodel,nor
isthestudyoftheimpactofdifferentcelltypes,likenormaland
tumorcells,onthePKandPDofthetherapeuticantibody.Both
tasks,however,arefeasibleatthe single celllevelusing kinetic
models of the targeted receptor system.
Kinetic model of in vitro ligand-receptor interaction
To describe the cell-level kinetics we use a canonical
model of ligand-receptor activation and trafﬁcking [19, 29,
20] which is parameterized using rate constants that have
been experimentally determined and validated in human
ﬁbroblast cells [29, 20] (Fig. 1b). The molecular species
R, Ri, L and RL denote the numbers of free receptors, free
internalized receptors, free extracellular ligand and ligand–
receptor complexes per cell, respectively. In the model, the
ligand L reversibly binds to the free receptors with asso-
ciation rate constant konL, and dissociate with rate constant
koffL. The free membrane receptors R are internalized with
rate constant kdegR and recycled with rate constant krecyRi or
degraded with rate constant kdegRi. The ligand–receptor
complex is internalized with rate constant kdegRL. The rate
of change of the different molecular species is given by:
dR
dt
¼ ksynR   konLR   L þ koffL   RL   kdegR   R þ krecyRi   Ri
ð4Þ
dRi
dt
¼ kdegR   R   krecyRi   Ri   kdegRi   Ri ð5Þ
dRL
dt
¼ konLR   L   koffLRL   kdegRLRL: ð6Þ
All molecular species are in number of molecules per cell,
except L which is in molar concentration. An EGF
concentration of L ¼ 2:36   10 3 nM was assumed [30].
a b Fig. 1 Schematic illustration of
the pharmacokinetic model and
the kinetic cell-level model.
a Semi-mechanistic
pharmacokinetic compartment
model describing the
pharmacokinetics of the the
mAb zalutumumab in monkeys
developed by Lammerts van
Bueren et al. [6]. b Canonical
model of ligand-receptor
activation and trafﬁcking
[19, 29, 20]
Table 1 Pharmacokinetic parameters determined in vivo by Lamm-
erts van Bueren et al. [16]
Name Deﬁnition Value Unit
Vpla Plasma volume 70 ml/kg
Vint Interstitial volume 35 ml/kg
kpi Rate constant of plasma-interstitial
transport
0.043 1/h
kip Rate constant of interstitial-plasma
transport
0.043 1/h
kb Constant thatensures quasi-steady
state conditions
0.069 1/h
Bmax,PK Whole-body capacity 2 mg/h/kg
KM,PK Half-maximal binding capacity in
vivo
0:5   10 3 mg/ml
kel Elimination of EGFR by
internalization and degradation
0.0055 1/h
qpi Plasma-interstitial transport Vpla   kpi ml/h
qip Interstitial-plasma transport Vint   kip ml/h
CLlin Target-independent drug clearance Vpla   kel ml/h/kg
Units were converted from mg to nmol using the scaling factor
SFmg!lmol ¼ 106=MWmAbs with MW_{mAbs = 148000 g/mol, i.e.,
1mg = SFmg!lmol  nmol
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123The model of ligand-receptor interaction can easily be
extended to account for the drug-receptor interaction by
including reactions for drug-receptor association and dis-
sociation (with rate constants konC and koffC) as well as
internalization and subsequent degradation of the drug-
receptor complex (with effective rate constant kdegRC), see
Fig. 2a. The extended cell-level model including the ther-
apeutic antibody Cex [in (nM)] in the extra-cellular space
with volume Vex, and the drug-receptor complex RC [in
(#molecules)] is given by:
Vex
dCex
dt
¼ koffC   SFunit   RC   konC   SFunit   R   Cex ð7Þ
dR
dt
¼ ksynR   konLR   L   konCR   Cex þ koffLRL þ koffCRC
  kdegR   R þ krecyRi   Ri ð8Þ
dRi
dt
¼ kdegR   R   krecyRi   Ri   kdegRi   Ri ð9Þ
dRL
dt
¼ konL   L   R   koffLRL   kdegRLRL ð10Þ
dRC
dt
¼ konC   Cex   R   koffCRD   kdegRC   RC ð11Þ
where the SFunit = 10
9/Navog denotes a scaling factor
from [#molecules] to [nmol] with Navo ¼ 6:02   1023 1/
mol denoting Avogardo’s constant. We included those
biological processes which are expected to have an
impact on the PK of the drug and provide a possibility
to link detailed systems biology model of downstream
signalling pathway.
To study the inhibitory potential of a therapeutic
antibody on a signalling pathway, realistic time-depen-
dent concentration time proﬁles are essential. As dis-
cussed, for many therapeutic antibodies, the targeted
system also has an inﬂuence on the time-course of the
antibody via receptor mediated drug uptake and degra-
dation. Hence, not only has the drug an effect on the
receptor system, but also does the receptor system
impact on the pharmacokinetics of the drug. As a con-
sequence, we herein propose a novel approach based on
integrating the single-cell level into compartment models
of antibody PK.
Linking whole-body and single-cell level
On the whole-body level, the interaction of zalutumumab
with its target is represented by a Michaelis Menten term
that describes the apparent drug-receptor interactions. At
the cellular level, this apparent interaction comprises
several kinetic processes, including association and dis-
sociation of the drug-receptor complex, internalization and
subsequent degradation of the internalized drug-receptor
complex. The assumption underlying our approach is that
the apparent drug-receptor interaction on the whole-body
level collectively represents the drug-receptor interaction
of all relevant cells at the cellular level, i.e., all target–
expressing cells that are exposed to the drug. The idea is
then to replace the apparent drug-receptor interaction in
the compartment model (1–3) by the detailed cell-level
model (7–11), scaled from the single-cell to the whole-
body level with the number of relevant cells. As a result
of this integration process, we obtained a cell-level PK/
PD model that allowed us to study the pharmacokinetics
on the whole-body level and at the same time the
inhibitory effect on the cellular level. For the integration,
we determined (i) the apparent drug-receptor interaction of
a single cell; and (ii) number of all relevant cells Ncell as
the scaling factor that links the apparent drug-receptor
interaction of a single-cell to the apparent drug-receptor
interaction of the whole-body level.
The apparent drug-receptor interactions of a single
cell was determined as the reduced description of the
cellular model (7–11) using the quasi-steady state
assumption on the receptor species R, Ri, RL and RC
(see, e.g, [28] for illustrative examples). This resulted in
the reduced model for the extra-cellular drug concen-
tration Cex, the membrane-bound amount of drug ARS
and the total drug concentration Ctot = Cex ? ARS/Vex,
where Vex denotes the extra-cellular volume associated
with a single cell:
Vex
dCtot
dt
¼  kdegRC  
Bmax;cell   Cex
KM;cell þ Cex |ﬄﬄﬄﬄﬄﬄﬄﬄ ﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ARS
ð12Þ
Cex ¼
1
2
CD þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðCDÞ
2 þ 4KM;cellCtot
q   
ð13Þ
with CD = Ctot - (Bmax,cell/Vex) - KM,cell. The parameters
Bmax,cell and KM,cell denote the maximal binding capacity of
a single cell and the concentration of drug at which the
binding capacity is half-maximally saturated. The model
reduction process also provided us with the relationship
between the effective parameters Bmax,cell, KM,cell and the
parameters of the original cellular model (7–11):
Bmax;cell ¼ SFunit  
ksynR
kdegRC
ð14Þ
KM;cell ¼
kdegRC þ koffC
kdegRC   konC |ﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
drug specific
 
kdegRikdegR
kdegRi þ krecyRi
þ L  
konL   kdegRL
koffL þ kdegRL
  
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
drug independent
: ð15Þ
Note that the maximal binding capacity Bmax cell is only a
function of the receptor system and independent of any drug
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depends non-linearly on both, receptor parameters as well
as drug parameters. Due to the above relationship (14–15),
we are able to explicitly compute the parametersBmax cell and
KM,cell based on the in vitro determined parameters
ksynR, kdegR, kdegRC, krecyRi, konL, koffL, kdegRL of the single-
cell model, the in vivo determined EGF concentration L,a n d
the drug-speciﬁc parameters konC, koffC, kdegRC.
We then determined the number of relevant cells N as
the factor that scales the single-cell binding capacity
Bmax,cell to the whole-body binding capacity Bmax,PK:
Bmax;PK ¼ Ncell   Bmax;cell: ð16Þ
Inserting the relationship (14)o fBmax,cell, we obtained
Ncell ¼
kdegRC   Bmax;PK
ksynR   SFunit
: ð17Þ
Note that all parameter values are known, so we may
explicitly determine Ncell from Eq. 17. In addition, we
deﬁned the in vitro-in vivo scaling factor SFiviv between
the concentrations of half-maximal binding capacity by
KM;PK ¼ SFiviv   KM;cell ð18Þ
The scaling factor SFiviv accounts for potential differences
between conditions in vitro and in vivo.
Next, we present our approach based on a single cell
type as a reference cell. We remark that the underlying
compartment model including the linear clearance part was
taken from the model by Lammerts van Bueren et al. as
stated in Eqs. 1–3. In the second part of this article we then
extend the cell-level PK/PD model to include multiple
reference cell type (tumor and normal cells). Along the
same lines, entire distributions of cell types could be
integrated e.g., to account for spatial inhomogeneities as
they are expected in solid tumors.
Cell-level pharmacokinetic/pharmacodynamic model
The presented approach allowed a systematic integration
of the single-cell level into the compartment model.
Based on the number of relevant cells Ncell, we replaced
the apparent drug-receptor interaction term in Eqs. 2, 3 by
the the drug-ligand-receptor model. The terms accounting
for the drug-receptor interaction were scaled to the whole-
body level by Ncell. The resulting single-cell PK/PD
model is given by:
Vpla
dCpla
dt
¼  qpiCpla þ qipCint   CLlin   Cpla ð19Þ
Vint
dCint
dt
¼þqpiCpla  qipCint
þNcell   koffC  SFunit  RC konC  SFunit  R Cint ðÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
whole bodysingle celllevel interaction
ð20Þ
dR
dt
¼ ksynR   konLR   L   konCR   Cint þ koffLRL
þ koffCRC   kdegR   R þ krecyRi   Ri
ð21Þ
dRi
dt
¼ kdegR   R   krecyRi   Ri   kdegRi   Ri ð22Þ
dRL
dt
¼ konL   L   R   koffLRL   kdegRLRL ð23Þ
dRC
dt
¼ konC   Cint   R   koffCRC   kdegRC   RC ð24Þ
thatdescribethe rate ofchangeofthe therapeutic antibody
in plasma Cpla and in the interstitial space Cint, the free
receptor R, the internalized receptor Ri, the drug-receptor
complexRC,theEGFligandintheinterstitialspaceLandthe
ligand-receptor complex RL. Rather than just re-estimating
parameters of the single-cell PK/PD model, the above
approach established a mechanistic link between the kinetic
model of the receptor system at the single-cell level and the
apparentterminthewhole-bodycompartmentmodel.Aspart
ofourapproach,weprovidedasystematicwayofdetermining
an apparent drug-receptor model from a detailed cell-level
description.Thishasbeenfurtherelaboratedin[28],wherewe
have also shown that the reduced model (12–13) is a more
appropriate description of the apparent drug-receptor
interaction in the compartment model (1–3), since it
eliminates the use of the artiﬁcial rate constant kb.
Measures of receptor saturation, residual activity
and inhibition
Receptor saturation by the drug, deﬁned as
receptor saturation ¼
RC
R þ RL þ RC
; ð25Þ
is often taken as a measure of the inhibitory potential of a
drug. We compared receptor saturation with the residual
receptor activation
residual receptor activity ¼
RL
RL ; ð26Þ
deﬁned relative to the pre-treatment level RL
* of activated
receptors.
We analyzed the impact of mAb treatment of target cells
with respect to three quantitative measures. The measures
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123of transient response are illustrated in Fig. 2c and are
deﬁned as follows:
– The integral of inhibition: Cumulative EGF receptors
that are not activated as a consequence of drug treat-
ment. More formally, the integral of inhibition is deﬁned
as area under the curve of the active receptors with
respect to their steady state pre-treatment level RL
*, i.e.,
E ¼
Z 1
0
ðRL    RLðtÞÞdt: ð27Þ
– The peak inhibition: Maximal reduction in activated
EGFR as a fraction of pre-treatment level RL
*:
peak ¼
RL    minfRLg
RL  : ð28Þ
– The duration of inhibition: Time needed to recover to
75% of the pre-drug level of activated receptors.
The chosen measures of inhibition resemble important
characteristics of drug effect. For small molecule drugs, the
integral of inhibition (exposure) is often related to the drug
effect, while the peak inhibition or the duration of inhibi-
tion (measuring some threshold characteristics) are often
related to the side effects.
For different cell types, e.g., normal and tumor cells, we
deﬁned the antibody speciﬁcity S as the ratio of the
inhibitory effect on tumor to normal cells. For the three
measures of transient response, this amounted to
SE ¼
Etumor
Enormal
;Sp ¼
peaktumor
peaknormal
;Sd ¼
durtumor
durnormal
; ð29Þ
where ’dur’ denotes duration.
Cell-level pharmacokinetic/pharmacodynamic model
with normal and tumor cells
To illustrate our approach and its potential application to
different cell types, we integrate tumor cells into the cell-
level PK/PD model. For this purpose, we consider only
tumor cells that are exposed to the same drug concentration
time proﬁle as normal cells. This assumption is expected to
hold for tumor cells close to the vasculature, but it is most
likely inadequate for cells in solid tumors (in which case
model the should be extended to account for a tumor dis-
tribution model). To compare the response of normal and
tumor cells to anti-EGFR antibodies, we extended our
model by integrating a kinetic cellular model representing
tumor cells with elevated EGFR levels (Fig. 2d). The rate
of change of all molecular species is given as follows,
L D
+
konC
koffC
ksynR
kdegR
+
konL
koffL
initializes 
downstream 
signalling
RL R RC
krecyRi
kdegRL
kdegRi
changes in 
gene 
transcription
Ri
receptor activation model
kdegRC
Cpla
ui(t)
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qip qpi
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Vint
ab
cd
Cpla
ui(t)
Cex
CLlin
qip qpi
Cint
Vpla
Vint
time
duration of inhibition
peak inhibition
a
c
t
i
v
e
 
r
e
c
e
p
t
o
r
s
/
c
e
l
l
integral of inhibition
Fig. 2 Schematic illustration of
the cell-level PK/PD model for
analyzing the inhibitory effect
on receptor activation of anti-
EGFR antibodies. a Cell-level
receptor model of receptor
activation and inhibition. The
cellular model describes the
transient inhibitory effect of a
therapeutic antibody by
competitively binding the
targeted receptor and thereby
decreasing the active ligand-
receptor complexes. b Cell-
level PK/PD model used to
study the trajectory of the drug
concentration and the impact of
biophysical properties of anti-
EGFR antibodies. c Three
different transient measures of
the reduction in the number of
active receptors: the integral,
the peak, and the duration of
inhibition. d Extended cell-level
PK/PD model including tumor
cells with elevated EGFR levels
due to alteration of receptor
dynamics used to compare the
inhibitory effect of therapeutic
antibodies on tumor cells and
normal cells to optimize tumor
speciﬁcity
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123where the subscripts N and T refer to normal and tumor
cells:
Vpla
dCpla
dt
¼  qpiCpla þ qipCint   CLlin   Cpla ð30Þ
Vint
dCint
dt
¼þqpiCpla qipCint
þNN  koffC SFunit RCN konC SFunit RN Cint ðÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
normalcells
ð31Þ
þNT   koffC   SFunit   RCT   konC   SFunit   RT   Cint ðÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
tumor cells
ð32Þ
dRN
dt
¼ksynR;N   konLRNL   konCRNCint þ koffLRLN
þ koffCRCN   kdegR;NRN þ krecyRiRiN ð33Þ
dRi;N
dt
¼ kdegR;N   RN   krecyRi   Ri;N   kdegRi   Ri;N ð34Þ
dRLN
dt
¼ konLL   RN   koffLRLN   kdegRL;NRLN ð35Þ
dRCN
dt
¼ konCCint   RN   koffCRCN   kdegRC   RCN; ð36Þ
dRT
dt
¼ksynR;T   konLRTL   konCRTCint þ koffLRLT
þ koffCRCT   kdegR;TRT þ krecyRiRi;T ð37Þ
dRi;T
dt
¼ kdegR;T   RT   krecyRi   Ri;T   kdegRi   Ri;T ð38Þ
dRLT
dt
¼ konLL   RT   koffLRLT   kdegRL;TRLT ð39Þ
dRCT
dt
¼ konCCint   RT   koffCRCT   kdegRC   RCT: ð40Þ
The parameters for tumor cells are identical to those of
normal cells, except for those speciﬁed below. Elevated
EGFR levels may be caused by a variety of alterations at the
target cell level. In the sequel, we analyzed the dynamics
response of two tumor cell types that have comparable ele-
vated EGFR levels prior to drug treatment: (i) cells with
increasedreceptorsynthesisrate(ksynR,Nvs.ksynR,T);and(ii)
cells with decreased receptor internalization (kdegR,N, kde-
gRL,N vs. kdegR,T, kdegRL,T). Both tumor cell types have been
observed experimentally [31– 34]. We set the number of
tumor cells to 1% of the normal cells so that it had little
impactonthepharmacokinetics(comparabletothesituation
in Bleeker et al. [25] in mice). The tumor cell model repre-
sents those tumor cells exposed to drug concentrations
equivalenttotheexposureofcellswithnormalEGFRlevels.
Methods
For the single-cell PK/PD model with normal cells only,
the system is assumed to be in steady state prior to any drug
administration, resulting in a number of free receptors R
*,
active receptors RL
*, and zero drug–receptor complexes
RC
* = 0. Similarly, for the model with normal and tumor
cells, the steady state levels are deﬁned by RN
*, RLN
*, and
RCN
* = 0, RT
*, RLT
*, and RCT
* = 0.
The response to a bolus dose C0 is obtained by numer-
ical integration of the corresponding system of ODEs with
the following initial conditions
RNð0Þ¼R 
N RTð0Þ¼R 
T Cpla ¼ C0
RLNð0Þ¼RL 
N RLTð0Þ¼RL 
T Cint ¼ 0
RCNð0Þ¼0 RCTð0Þ¼0:
For numerical simulations, we used the parameter values
given in Table 2. The model was build and simulated using
MATLAB (R2011b).
Results
Predicting the inhibitory effect of the anti-EGFR
therapeutic antibody zalutumumab in cynomolgus
monkeys
We determined a single-cell PK/PD model for the anti-
EGFR therapeutic antibody zalutumumab in cynomolgus
monkeys. The model based on in vivo data for zal-
utumumab in cynomolgus monkeys [6], in vitro data of
human ﬁbroblast cells [29, 20] and determined drug-
receptor afﬁnities [35]. Importantly, our approach does not
involve any ﬁtting of parameters; all parameter values were
either inherited from the original compartment model,
determined in vitro, or explicitly calculated.
Evaluation against in vivo data
To evaluate the single cell PK/PD model, we compared our
model predictions with the experimental data of zal-
utumumab in cynomolgus monkeys. Based on the descri-
bed integration process, we determined the number of
relevant cells as Ncell ¼ 5:2   109 and the in vitro-in vivo
scaling factor as SFiviv = 2.1. The small scaling factor
SFiviv was considered as supporting evidence for the cho-
sen single-cell model. Furthermore, the predicted time-
courses of the drug concentrations showed very good
agreement for the high, medium and low dose of 40 mg/kg,
20 mg/kg and 2 mg/kg dose (Fig. 3a).
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123At the same time, the cell-level pharmacokinetic model
was used to predict the dynamics of the receptor system
upon drug administration (Fig. 3b). In agreement with
experimental ﬁndings reported in [6] (Table 3), the model
predicted that a saturation in monkey tissue which
expresses normal receptor levels was established at doses
between 2 and 20 mg/kg (Fig. 3b, inset). We considered
the agreement between our model and the data available in
[6] as validation to proceed conﬁdently in our study. The
available data considers 2 and 20 mg/kg doses, and
therefore in the sequel we will restrict our analysis to these
doses only.
Predicting residual EGFR activity per cell
The cell-level PK/PD model then was used to predict the
number of activated receptors over the duration of the
treatment, which is difﬁcult to examine in vivo. Our model
predicted that the low dose (2 mg/kg) of antibody reduces
the number of active receptors by about 35%. The steep
initial decrease in receptor activation is followed by a
recovery period secondary to a slow reduction of drug
concentration (Fig. 3b). On the other hand, the higher dose
(20 mg/kg) almost completely inhibited receptor activation
for a period of about 20 days. The start of the recovery
period coincided with the transition from saturated to linear
pharmacokinetics between days 20 and 25. The model
therefore suggests that changes in pharmacokinetics mays
act as a biomarker for changes in the inhibitory response.
Comparing receptor saturation (25) with residual
receptor activity (26), we found that both characteristics
only corresponded initially, while at later points in time the
receptor saturation underestimated the inhibitory effect of
the antibody (e.g. compare with the 20 mg/kg dose after 50
days). This highlights the importance of adopting an
integrated kinetic model to translate the binding of the drug
into its actual inhibitory effect on receptor activation.
Impact of drug characteristics on receptor inhibition
One advantage of the cell-level PK/PD model is its ability
to predict the impact of drug properties such as the dose,
drug-receptor afﬁnity, and drug induced receptor internal-
ization on the inhibitory response under in vivo conditions.
We assumed that the target independent PK distribution
parameters Vpla, Vint, qpi and qip do not change when
changing properties of the F(ab) region. Since all the
analyzed antibodies are either of IgG1 or IgG2 isotype,
their target-independent clearance was also assumed to be
identical [36].
Afﬁnity and dose
We studied the inhibitory effect for a range of afﬁnities,
including those of anti-EGFR mAbs on the market or in
clinical development: zalutumumab, panitumumab, cetux-
imab, IMC-11F8, and nimotuzumab (see Table 4). All
these antibodies act antagonistically [37]. Different afﬁni-
ties KD were realized by changing the dissociation rate
constant koffC, while the association rate constant konC was
assumed to be diffusion-limited and therefore left
unchanged. Our analysis focused on the F(ab)-mediated
direct inhibitory effect, i.e., on the reduction in the number
of activated receptors at the cell membrane.
The percentage of active receptors over time is shown in
Fig. 4a. Despite 20-fold differences in target afﬁnities (see
Table 4), the transient inhibition pattern were surprisingly
similar. As can be seen in Fig. 4b–d, this phenomenon is a
consequence of an effect plateau in the inhibitory respon-
ses. For high afﬁnity drugs located in the plateau range, an
increased afﬁnity does not translate into a noticeable
Table 2 Parameter values for the EGF receptor system
Name Deﬁnition Value Unit References
konL Ligand–receptor binding 7:2   10 2 1/(nM min) [20]
koffL Ligand–receptor unbinding 0.34 1/min [20]
kdegR Free receptor internalization 0.03 1/min [20]
kdegRL Ligand–receptor complex internalization 0.03 1/min [20]
kR,N Receptor expression rate in normal cells 130 Receptors/min per cell [20]
krecyRi Free receptor recycling 5:8   10 2 1/min [20]
kdegRi Free receptor degradation 2:2   10 3 1/min [20]
konC Drug–receptor binding konL 1/(nM min)
kdegRC Drug–receptor complex internalization 0.005 1/h [6]
MWmAbs Molecular weight 148000 Dalton (g/mol)
For monkeys, krecyRi and kdegR were multiplied by a factor of 4 and 1/4, respectively to account for species differences
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123stronger inhibition. Mathematical analysis of the model
(Appendix) for the integral effect suggests that this is a
structural feature of the system that does not depend on
speciﬁc parameter values. Shankaran et al. [19] identiﬁed
the ‘‘consumption parameter’’, i.e, the ratio of the disso-
ciation and downregulation rate constants (kdegRC/koffC), as
a key parameter to characterize cell surface receptor
systems. It quantiﬁes the likelihood that a drug, upon
binding the receptor, is internalized rather than dissociated.
We found that this is also an important parameter for
antagonistic mAbs, since those with a high consumption
parameter are located on the effect plateau such that their
F(ab)-mediated direct inhibitory effect could not be further
increased. When decreasing the afﬁnity of the mAb, the
clearance effect of binding and internalization became less
important than the target independent clearance. As a
consequence we found that the drug effect, which is related
to receptor binding, decreases for lower afﬁnity.
Downregulation
Receptor downregulation denotes the drug-induced process
of the reducing the number of free receptor at the membrane
that is available for binding to the natural ligand. Enforcing
receptor downregulation by therapeutic antibodies is argued
to be an important part of the drug effect [17]. In Fig. 4b–d,
we predicted the inhibitory effect of antibodies with a 5-fold
and 10-fold increased internalization rate constant (relative
to the rate constant of zalutumumab) for different afﬁnities
and low and high doses. We found that for high-afﬁnity
antibodies, receptor downregulation only contributes to a
negligible extent to the F(ab)-mediated direct inhibitory
effect. For medium afﬁnity antibodies, however, an
increased downregulation rate constant could increase the
direct inhibitory effect to some extent.
Tumor cell speciﬁcity
Upregulation of EGFR expression and aberrant activation
of EGFR has been shown in many human epithelial
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Fig. 3 Pharmacokinetics of zalutumumab in cynomolgus monkeys
and prediction of the inhibitory effect on a cellular level using
themodel depicted in Fig. 2b. a Predicted plasma concentration of
zalutumumab by the cell-level PK/PD model (solid line) and the
compartment PK model of Lammerts van Bueren et al. [6]( dashed
line) for a high, medium and low dose of 40, 20 and 2 mg/kg. The
experimental data for zalutumumab in cynomolgus monkeys are
marked with circles (40 mg/kg), squares (20 mg/kg) and diamonds (2
mg/kg). Experimental data courtesy of Wim Bleeker, Genmab,
Utrecht, The Netherlands. b Predictions of the residual EGFR
activation per cell based on the cell-level pharmacokinetic model
(Fig. 2b) for the high dose (dashed dotted line), the medium dose
(solid line) and the low dose (dashed line). The inset depicts the
corresponding receptor saturation according to Eq. 25
Table 3 Pharmacodynamics of zalutumumab in cynomolgus mon-
keys for different doses as reported in Lammerts van Bueren et al. [6]
and predicted by the single-cell PK/PD model (see Fig. 3)
Dose (mg) In vivo experiment In silico prediction
2 Not fully saturated Max. 60 % saturated
20 Fully saturated 100% saturated
40 Fully saturated 100% saturated
Table 4 Afﬁnities and isotypes of the different therapeutic antibod-
ies against the EGFR. Values taken from Peipp et al. [35]
Antibody Afﬁnity/avidity (M) Isotype
Panitumumab 5   10 11 IgG2
Cetuximab 4   10 10 IgG1
IMC-11F8 3   10 10 IgG1
Nimotuzumab 1   10 9 IgG1
Zalutumumab 7   10 9 IgG1
The KD (afﬁnity) values were subsequently scaled with SFiviv, i.e.,
KDðinvivoÞ¼SFiviv   KDðinvitroÞ to account for differences between
conditions in vitro and in vivo. While potentially the scaling factors
for KM (see Eq. 18) and KD could be different, we used the same
scaling factor SFiviv due to lack of further information and based on
the principle of parsimony. See also footnote to Table 1 of [35],
where afﬁnity values are reported
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123cancers, including those of the colon, lung, kidney, head
and neck, breast, prostate, brain and ovary [38–43]. The
extent of overexpression also correlates with a poorer
clinical outcome [44, 45].
The cellular model for the tumor cells with increased
receptor synthesis was chosen to resemble the character-
istics of A431 cells, a human squamous carcinoma cell line
with high EGFR levels [31– 33]. The overexpression in
A431 cell is due to ampliﬁcation of the EGFR gene [46]
and correlates with increased EGF receptor mRNA levels
[32]. A431 cells express about 10 times more EGFR at the
cell surface than normal cells [31]. The cellular model for
the tumor cells with decreased receptor internalization was
chosen to resemble the characteristics reported in [34].
Reddy et al. [34] report about an alteration of EFGR where
a truncated cytoplasmic domain exhibits a decreased
ligand-induced internalization rate constant. Figure 5a
illustrates the predicted inhibitory effect in tumor and
normal cells in cynomolgus monkeys.
Figure 5b compares the predicted transient inhibition for
both alterations, increased synthesis rate and reduced inter-
nalization.Forbothalterations,theinhibitoryeffectisstrong
er for tumor cells than for cells with nor mal EGFR levels.
Althoughbothcellalterationsresultedinsimilarsteady-state
activation levels, their responses to mAbs are remarkably
different with cells with decreased receptor internalization
showing a higher integral and duration of inhibition com-
pared to cells with an increased synthesis of the receptor.
Discussion
The objective of this article was to develop a systematic
approach to integrate the cellular-level into compartment
models of drug PK, and to apply the approach to analyze
the F(ab)-mediated inhibitory effect of therapeutic anti-
bodies in cancer therapy.
Several mAbs on the market have a high receptor
afﬁnity in the sub-nM range, but the traditional design
criterion that ‘‘the best binder makes the best drug’’ has
been challenged [47–49]. Using our combined model we
evaluated the effect of different afﬁnities of antibodies
targeting the EGFR. In cynomolgus monkeys, our cell-
level PK/PD model predicts almost identical F(ab)-medi-
ated direct inhibitory effects for a range of antigen-binding
afﬁnities. Since current anti-EGFR antibodies are located
on the observed effect plateau, this relativizes the afﬁnity
amongst the properties that could be further tuned to
optimize antibody efﬁcacy.
A high afﬁnity is thought to allow panitumumab to
compete more effectively with EGF in binding to EGFR
and to saturate EGFR in vivo at lower doses relative to
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Fig. 4 F(ab)-mediated
inhibitory effect of different
antibodies using the cell-level
PK/PD model shown in Fig. 2b.
a Predicted transient inhibitory
effects of ﬁve anti-EGFR
antibodies on the market or in
clinical development with
different afﬁnities (see Table 3)
for a 20 mg/kg dose (solid line)
and a 2 mg/kg dose (dashed
line). The different mAbs show
a similar transient inhibitory
effect despite their afﬁnities
vary 20-fold. b–d Inhibitory
effect resulting from different
afﬁnities (KD = 1/afﬁnity =
koffC/konC) and
downregulation rates (kdegRC).
The F(ab)-mediated effect is
quantiﬁed by three different
measures: b the integral of
inhibition, c the peak inhibition,
and d the duration of inhibition,
for the 20 mg/kg dose (solid
line) and 2 mg/kg dose (dashed
line). The shaded area indicates
the afﬁnity range of the ﬁve
considered antibodies
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123mAbs with lower afﬁnity [16]. This is not supported by our
analysis, and instead our ﬁndings predict that the F(ab)-
mediated effect of panitumumab and cetuximab are com-
parable. This prediction of the model is in agreement with
experimental results by Messersmith and Hidalgo [50]. We
further investigated if this result is due to the speciﬁc
values of the parameters we used to simulate the model by
calculating an analytically solution of the integral of the
effect. The analytical solution shows that the existence of
an effect plateau is a generic feature of this drug-target
system and does not depend on speciﬁc parameter values.
Therefore this result suggest that such an effect plateau
might exist for other receptor systems with receptor
trafﬁcking.
Crombet et al. [48] argued that the low degree of
adverse effects observed for Nimotuzumab in the clinics is
due to its intermediate afﬁnity compared to other anti-
EGFR antibodies. Their conclusions are based on a math-
ematical model that only takes into account receptor
binding, but neglects the important process of receptor
internalization and target speciﬁc degradation. Based on
our single-cell PK/PD model for cynomolgus monkeys, we
ﬁnd that an intermediate afﬁnity does not result in opti-
mized tumor effect or speciﬁcity. Recently, Talavera et al.
[51] suggested an alternative explanation for the low
degree of adverse effects observed for Nimotuzumab.
Based on the existence of an effect plateau in the F(ab)-
mediated direct inhibitory effect, our ﬁndings suggest that
theclinicallyobserveddifferencesamongmAbsarelikelyto
arise from Fc-mediated indirect effects, such as the action of
immune effector functions (such as antibody dependent cell
mediated cytotoxicity or complement dependent cytotoxic-
ity), rather than the direct antagonistic effect. This is con-
sistent with a study of Bleeker et al. showing that effects in
vivo of zalutumumab and cetuximab differed only by their
ability to trigger such indirect effect and not by their direct
inhibitoryeffect[25].Possibleextensionsofthemodelcould
address the likelihood of triggering such Fc-mediated indi-
rect effects. Since the model predicts the time course of the
different receptor species, it may serve as a starting point to
estimate the proportion of bound antibody that are presented
to the extracellular space and trigger Fc-mediated immune
effects.
Alterations of a number of kinetic processes can result in
elevated EGFR levels. The combined systems biology/
pharmacokinetic model allows us to study two different
tumor cell alterations with elevated EGFR levels resulting
from (i) an increased receptor synthesis rate; and (ii) a
decreasedreceptorinternalizationrate.Bothtypeshavebeen
observedexperimentally[46,32,34].Wefoundthatreceptor
inhibition over time strongly depends on the underlying
molecular alteration that caused the elevated EGFR level.
Our in silico studies show that the inhibitory effects at
normal and tumor cells are correlated, and therefore sup-
port the hypothesis that the side effects may serve as a
marker for the desired effect at the tumor cells. This is in
line with experimental observations that the most common
side effect of anti-EGFR antibodies are cutaneous toxici-
ties, affecting 45–100% of patients [52]. Since this skin
rash follows from the inhibition of epidermal cells
expressing normal levels of the EGFR, using the rash as a
marker of drug activity and clinical outcome was proposed
[53] and our theoretical study supports this.
The compartment model (1–3) describes the distribution
of the drug to the target expressing cells. In this case we
described distribution as reversible linear process as pre-
viously done when relating plasma concentration to
potential pharmacodynamic effect [54]. However,
integral peak duration
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Fig. 5 The mechanism underlying increased receptor levels inﬂu-
ences tumor speciﬁcity of mAbs. a Predicted transient inhibition
based on the extended cell-level pharmacokinetic model shown in
Fig. 2d for normal cells, tumor cells with a 10-fold increased receptor
expression, and tumor cells with a 10-fold decreased internalization of
the free and bound receptor. Proﬁles are shown for the 20 mg/kg
(solid line) and 2 mg/kg (dashed line) dose. Both scenarios show
similar steady-state activation levels of the receptor, but their
response to drug treatment is substantially different. b Antibody
speciﬁcity as deﬁned in Eq. 29. Cells with a decreased receptor
internalization have a much longer duration of inhibition and
therefore a higher integral of inhibition than tumor cells with an
increased receptor expression
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123processes such as convective movement, lymphatic circu-
lation and ﬁlter effects can affect the distribution of anti-
bodies. In these cases, detailed models for antibody
distribution e.g. a two pore model (Rippe and Haraldsson,
1994, Physiological reviews) could be integrated into the
model. Further, predictions of EGFR inhibition in tumor
cells are limited to those malignant cells which are exposed
to similar concentrations than normal cells, such as avas-
cular metastases embedded in healthy tissue [55, 56]. In
solid tumors, due to heterogeneous drug distribution, only
malignant cells close to capillaries may be exposed to such
concentration. Taken together, more detailed models of
mAbs distribution, such as physiologically based pharma-
cokinetics models [57, 58], should be included in cases
where distribution of the drug to target cells can not be
described by reversible linear processes. The current model
also predicts only the decrease in receptor activation rather
than the actual biological response of the cell. While
Knauer et al. [29] reported a linear dependence between
the number of activated EGFR at steady-state and the
cellular responses of ﬁbroblasts and epithelial cells, other
models describe a more complex relationship between
receptor activation and downstream signalling [59].
Established models to study antibody pharmacokinetics
include models of TMDD (e.g., Gibiansky et al. [8, 9]). Our
cell-level PK/PD model has three important differences
compared to TMDD models. First, the model includes the
competition of natural ligands with the antibodies for the
binding to the receptor. This allows us to study the change
of the number of receptor-ligand complexes due to the drug
treatment. Second, the model includes more details of the
cellular mechanisms. For example, the internal pool of
receptors and the recycling to the cell surface are part of the
detailed receptor trafﬁcking model, but not of current
models of TMDD. We investigated if we could remove this
pool together with receptor recycling to make the model
more TMDD-like. However, we found this internal pool to
be important to describe the initial PK without reﬁtting of
the experimentally derived parameters. Our ﬁndings sup-
port the hypothesis in [6] stating that ‘‘possibly, EGFR
surface expression can temporarily be replenished with
EGFR present in the cell’’. Third, and most notably, our
cell-level PK/PD model integrates in vitro determined
parameter values instead of ﬁtting all parameters to the in
vivo data. This is useful to avoid over-paramerization of the
model, which has be reported to be a critical problem when
using the original TMDD model [8].
Combining modelling approaches from pharmacokinet-
ics and systems biology allows us to quantitatively analyse
the dynamic interaction between drugs and biological
systems [15]. One remaining question concerns the vali-
dation of multi-level models. We here used the approach to
validate the model prediction using pharmacokinetic data
while integrating an in vitro validated cell-level model.
Furthermore, we validated the full model using available
PK data together with limited PD data. Ideally however,
validation should be done using datasets that integrate
pharmacokinetic and cell-level data (e.g. receptor phos-
phorylation) from one source.
We envision that a cell-level PK/PD modeling approach
will prove valuable in the emerging ﬁeld of systems phar-
macology. The use of more detailed systems biology models
describing downstream signaling processes relevant to
humandiseases[13,60,61]mayeventuallyallowtotranslate
plasma drug concentration into responses of tumor cells.
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Appendix
Theoretical analysis of the integral of inhibition
The inhibitory effect can be studied by looking at the
response of the model linearized around the steady state
activation level. In what follows we derive a formula for
the integral of inhibition in the linear system, which pro-
vides an estimate for that of the original system.
The steady state of model (20–40)i s
x  ¼½ C 
int C 
pla R 
N R 
i RL 
N RC 
N R 
T R 
i;T RL 
T
RC 
T ;
and we know that Cint
* = Cpla
* = RCN
* = RCT
* = 0. We
assume that the steady state is exponentially stable, which
for any realistic scenario is trivially satisﬁed. This
guarantees that the integral of the inhibition
E ¼
Z 1
0
ðRL 
N   RLNðtÞÞdt; ð41Þ
is a ﬁnite number. The deviations of the model variables
with respect to the steady state are
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123  RN ¼ R 
N   RN   RT ¼ R 
T   RT   Cpla ¼  Cpla
  Ri ¼ R 
i   Ri   Ri;T ¼ R 
i;T   Ri;Y   Cint ¼  Cint
  RLN ¼ RL 
N   RLN   RLT ¼ RL 
T   RLT
  RCN ¼  RCN   RCT ¼  RCT
We deﬁne a state vector as
  x ¼½  Cpla   Cint   RN   Ri   RLN   RCN   RT   Ri;T   RLT   RCT 
T ð42Þ
Linearizing the model around the steady state leads to
d  x
dt
¼ A  x: ð43Þ
The matrix A 2 R10 10 is given in Eq. 53 and
corresponds to the Jacobian of the right hand side of
(30–40) evaluated at the steady state. Integration of (43)
from t = 0u pt ot ¼1gives
  xð1Þ     xð0Þ¼A
Z 1
0
  xðtÞdt: ð44Þ
For a bolus dose C at t = 0 the initial condition for (43)i s
  xð0Þ¼½   C 00...0 
T: ð45Þ
The stability of the equilibrium implies that   xð1Þ ¼ 0,
which upon substitution in (44) yields
Z 1
0
  xðtÞdt ¼  A 1  xð0Þ: ð46Þ
From (42) we notice that the integral of inhibition E is the
5th entry of the vector in (46). Hence
E ¼
Z 1
0
  x5ðtÞdt ¼  ½ A 1  xð0Þ 5: ð47Þ
Computing the inverse A 1 we get
E ¼
aRL 
N
b þ c 1
konC
1
CP þ 1
   ; ð48Þ
with the constants:
a ¼ VplaR 
NqcpC
kdegR
konLL
koffL þ kdegRL
krecyRi þ kdegRi
  
; ð49Þ
b ¼ ksynR;NSFunitðqcp þ CLlinÞðNNR 
N þ NTR 
TÞð 50Þ
c ¼ kR;NCLlinqpc ð51Þ
The parameter Kd = 1/afﬁnity and the ‘‘consumption
parameter’’ deﬁned by in [19] are given by
KD ¼
koffC
konC
CP ¼
kdegRC
koffC
: ð52Þ
The effect E is a decreasing function of koffC and shows
little variations for the values of KD for the mAbs in
Table 4. All these mAbs are located in a plateau region of
the effect E. This linear analysis suggests that the effect
plateau is a structural feature of the system and does not
depend on the parameter values.
a11 ¼
 1
Vc
ðqcp þ CLlinCÞð 54Þ
a22 ¼
 1
Vp
ðkonCNNSFunitR 
N þ konCNTSFunitR 
T þ qpcÞð 55Þ
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